PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — FY2013 Earnings Presentation
19 slides from PT Kalbe Farma Tbk's earnings presentation, February 2014
Slide 1: Analyst Gathering February 2014
Tasty way to reduce cholesterol Analyst Gathering February 2014
Slide 2: Table of Contents
Table of Contents BUSINESS OVERVIEW 3 INDICATIVE 2013 RESULTS & 2014 OUTLOOK 12 Excellence in Execution 2
Slide 3: Section 1: Business Overview
Tasty way to reduce cholesterol SECTION 1 Business Overview
Slide 4: Macro Overview
MACRO OVERVIEW Macro Environment 2013 Indonesian Healthcare Spending Rupiah – US Dollar (Exchange Rates on Transaction) Roll-out of National Healthcare Insurance - January 1, 2014 2019 Target: 100% population – $$$ 2014 250 million people Rp Minimum Target: 50% population – Fuel Skim Milk 121.6 mill
Slide 5: Business Strategies and Corporate Branding
BUSINESS STRATEGIES 1. Improve marketing and sales effectiveness CORPORATE Diabetasol Fun Walk 2013, Fatigon Aksi Semangat 2013, BRANDING 34,000 participants in 28 cities 40,000 participants in 3 major cities 2. Strengthen business portfolio through innovation and M&A 5 Excellence in Execution
Slide 6: Business Strategies
BUSINESS STRATEGIES 4. Go global – deeper ASEAN penetration with 3. Expand distribution coverage more product offering New branches and Additional trucks & New RDC existing branch capacity motorcycles expansion 5. Enhance human capital development Excellence in Execution 6
Slide 7: 2013 Highlights
2013 HIGHLIGHTS Strengthening production and Getting closer to our consumers distribution network Completed oncology Increased Direct to Consumer (DTC) production facilities production lines Activities 2013 at Pulogadung and capacities Diabetasol Entrasol Upgraded distribution facilities Pontianak C
Slide 8: 2013 Highlights
2013 HIGHLIGHTS Expanding customer touch points Kalbe e-Store Kalbe Home Delivery Kalbe Family Rewards Card KalCare Activities 8 KalCare Experiential Store Health Seminars Pre-school Field Trip KalbeMed Mobile Application Excellence in Execution
Slide 9: 2013 Highlights
2013 HIGHLIGHTS Strenghtening Product Portfolio through Innovation New Product Launches Research & Development Stem Cell and Cancer Institute Excellence in Execution 9
Slide 10: 2013 Highlights: Cancellation of Treasury Stocks
2013 HIGHLIGHTS Cancellation of Treasury Stocks The treasury stocks have been cancelled in EGMS in May 2013. Outstanding Shares Number of Shares before cancellation 50,780,072,110 Number of Treasury Stocks cancelled (7.7%) 3,904,950,000 Number of Shares after cancellation 46,875,122,110 The treasury
Slide 11: 2013 Highlights
2013 HIGHLIGHTS Looking after all our stakeholders – more than 400,000 participants Kalbe Junior Science Fair 2013 Environmental Sustainability Consumer Protection ISO 14001:2004 Certified Environmental Management Dedicated Customer System Care Team Kalbe Care Attended by more than 84,000 visitors K
Slide 12: Section 2: Indicative 2013 Results & 2014 Outlook
Tasty way to reduce cholesterol SECTION 2 Indicative 2013 Results & 2014 Outlook
Slide 13: Consolidated Sales
Consolidated Sales Strong Top Line Growth of Internal Kalbe Products Net Sales (in Rp Bn) 17.4% 31 Dec 2012 (Audited) 16,008 31 Dec 2013 (Unaudited) 13,636 12.6% 17.7% 25.9% 16.6% 5,188 5,842 3,288 3,869 3,012 3,792 2,149 2,505 Prescription Consumer Health Nutritionals Distribution & Consolidation P
Slide 14: Consolidated Operating Performance
Consolidated Operating Performance Stable Margin Gross Profit Margin Operating Expenses to Net Sales Ratios 31.6% 32.1% 47.9% 47.9% 0.7% 0.9% 4.8% 4.7% Selling & 31 Dec 2012 31 Dec 2013 Marketing (Audited) (Unaudited) General & 26.2% 26.5% Administrative Operating Profit Margin Research & Developmen
Slide 15: Consolidated Net Earnings
Consolidated Net Earnings Sustainable Earnings Growth Income Before Tax Net Income (in Rp bn) (in Rp bn) + 10.8% 2,558 +10.8 % 2,308 1,734 1,922 31 Dec 2012 31 Dec 2013 31 Dec 2012 31 Dec 2013 (Audited) (Unaudited) (Audited) (Unaudited) • Income before tax margin declined from 16.9% in FY 2012 to •
Slide 16: Working Capital Management
Working Capital Management A Temporary Spike in Working Capital Temporarily higher level of raw 158 materials inventory and impact No. of days of Rupiah depreciation 129 132 120 108 142 114 134 122 110 115 107 Net Operating Cycle has been decreased by 26 days from 158 50 days in 2008 to 132 days in
Slide 17: Solid Financial Position
Solid Financial Position Rp 0.85 Trillion of Net Cash Position Total Debt and Gearing Ratio Cash & Net Cash Balance 2,291 2,151 1,902 1,860 1,877 1,655 1,562 1,433 1,322 1,222 600 11.2% 15.0% 917 500 850 400 7.9% 7.2% 10.0% 300 200 2.3% 2.9% 5.0% 0.5% 100 405 340 25 141 205 583 0 0.0% FY 2008 FY 200
Slide 18: Outlook 2014
OUTLOOK 2014 Earnings Guidance 2014 1. Year-on-year Sales Growth 14% - 16% 2. Operating Profit Margin 16.0%-17.0% 3. Earnings per Share growth of 15% - 17% * 4. Dividend payout ratio minimum 40% * Excluding the impact from foreign exchange translation Capex Rp 1 – 1.2 Tn for production capacity and
Slide 19: Thank You
THANK YOU For further information: PT Kalbe Farma Tbk. Jalan Let.Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email : vidjongtius@kalbe.co.id kartika.setiabudy@kalbe.co.id investor.relations@kalbe.co.id Website : www.kalbe.co.id Excellence in Execution 1